{"nctId":"NCT00605085","briefTitle":"Safety and Tolerability of the Japanese Encephalitis Vaccine IC51","startDateStruct":{"date":"2005-10"},"conditions":["Japanese Encephalitis"],"count":2675,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Japanese Encephalitis purified inactivated vaccine (IC51)"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"Japanese Encephalitis purified inactivated vaccine (IC51)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Written informed consent obtained prior to study entry\n\nExclusion Criteria:\n\n* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine\n* History of any previous JE vaccination (e.g. JE-VAXÂ®)\n* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy\n* A family history of congenital or hereditary immunodeficiency\n* History of autoimmune disease\n* Any acute infections within 2 weeks prior to enrollment\n* Known or suspected HIV Infection\n* Pregnancy, lactation or unreliable contraception in female subjects","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability up to Day 56","description":"calculation based on safety population, numbers provide percentages of participants with Adverse Events (AEs)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.9","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Serious Adverse Events and Medically Attended Adverse Events","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"SCR and GMT of Subjects With Concomitant Vaccinations","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":1993},"commonTop":["Headache","Myalgia","Influenza Like Illness","Fatigue","Nausea"]}}}